J&J submits NDA for fixed-dose diabetes product

Janssen Research & Development LLC submitted an NDA to FDA for a fixed-dose combination of canagliflozin and immediate-release metformin to treat Type II diabetes. An NDA for Invocana canagliflozin, a...